Prognostic model of rapid hepatic fibrosis progression in men with chronic hepatitis C
DOI:
https://doi.org/10.14739/2310-1237.2019.1.166214Keywords:
chronic hepatitis C, hepatic fibrosis, men, prognosis, TLR7 geneAbstract
The aim of the research was to determine clinical and genetic predictors and to create a prognostic model for the rapid hepatic fibrosis progression in men with chronic hepatitis C.
Materials and methods. А cross-sectional study which included 111 male patients with chronic hepatitis C was conducted. The patient examination program included: assessment of complaints and anamnestic data, physical examination, complete blood count, biochemical test, the stages of hepatic fibrosis according to METAVIR аnd genetic studies (detecting carriers alleles 11Gln or 11Leu of TLR7 gene in the genome of the examined men).
Results. It was determined that informative predictors of rapid hepatic fibrosis progression in men with chronic hepatitis C are: ethanol use in a dose of more than 40 g/day (ОR = 2.40, P = 0.042), presence of chronic cholecystitis in past history (ОR = 2.94, P = 0.013), ALT level above 3 upper limit of normal (ОR = 2.49, P = 0.031), the levels of AST, GGT exceeding upper limit of normal (ОR = 6.94, P < 0.001 and ОR = 4.02, P = 0.001 respectively), hyperbilirubinemia (ОR = 3.13, P = 0.010) and carrier state of allele 11Gln of TLR7 gene in the genome (ОR = 3.62, P = 0.036). In order to optimize the prognosis of rapid hepatic fibrosis progression in men with chronic hepatitis C a model that demonstrated statistical significance (χ² = 44.73, P < 0.001) and high operational characteristics (sensitivity – 76.8 %, specificity – 74.5 %, the total number of correct predictions – 75.7 %, AUC of the ROC-curve – 0.828), which indicates the feasibility of its practical use, was proposed.
Conclusions. An effective clinical and genetic prognostic model has been created and allows us to predict the probability of rapid hepatic fibrosis progression in men with chronic hepatitis C with high accuracy and to form a group of patients who need high priority antiviral therapy.
References
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection (2014). J Hepatol., 60, 392–420.
Musin, A. G., Mutalova, E. G., Nigmatullina, A. E., Konstantinova, E. E., Musina, F. S., & Nasibullin, I. M. (2014). Sovremennye aspekty mekhanizmov fibrogeneza v pecheni [Modern aspects of liver fibrogenesis mechanisms]. Medicinskij vestnik Bashkortostana, 9(3), 95–99. [in Russian].
Poynard, T., Bedossa, Р., & Opolon, Р. (1997). Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOS-VIRC groups. Lancet, 349(9055), 825–832.
Sebastiani, G., Gkouvatsos, K., & Pantopoulos, K. (2014). Chronic hepatitis C and liver fibrosis. World journal of gastroenterology:WJG., 20(32), 11033–11053. doi: 10.3748/wjg.v20.i32.11033
Howell, J., Angus, P., Gow, P., & Visvanathan, K. (2013). Toll-like receptors in hepatitis C infection: Implications for pathogenesis and treatment. J Gastroenterol Hepatol., 28(5), 766–776. doi: 10.1111/jgh.12170
Kawai, Т., & Akira, S. (2013). Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity, 34(5), 637–650. doi: 10.1016/j.immuni.2011.05.006
Roh, Y. S., Park, S., Kim J. W., Lim, C. W., Seki, E., & Kim, B. (2014). Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis. Hepatology, 60(1), 237–249. doi: 10.1002/hep.26981
Sasai, M., & Yamamoto, М. (2013). Pathogen recognition receptors: ligands and signaling pathways by Toll-like receptors. Int Rev Immunol., 3(2), 116–133. doi: 10.3109/08830185.2013.774391
Xu, Y., & Zhong, J. (2016). Innate immunity against hepatitis C virus. Curr Opin Immunol., 42, 98–104. doi: 10.1016/j.coi.2016.06.009
Askar, E., Ramadori, G., & Mihm, S. (2010). Toll-like receptor 7 rs179008/Gln11Leu gene variants in chronic hepatitis C virus infection. J Med Virol., 82(11), 1859–1868. doi: 10.1002/jmv.21893
Bordignon, M., Bargagli, E., Agostini, C., Cinetto, F., Baldo, V., Alaibac, M., et al. (2013). TLR7 Gln11Leu single nucleotide polymorphism in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis., 30(2), 157–161.
Dubinskaya, G. М., Sizovа, L. М., Koval, T. І., & Izyumskaya, E. M. (2016). Vplyv polimorfizmu heniv TLR4 ta TLR7 na shvydkist prohresuvannia fibrozu pechinky u khvorykh na khronichnyi hepatyt С [The influence of TLR4 and TLR7 gene polymorphisms on the rate of liver fibrosis progression in patients with chronic hepatitis C]. Hepatolohiia,
(31), 23–32. [in Ukrainian].
Dubinskaya, G., Sizova, L., Koval, Т., Kovalyova, Е., & Kaydashev, I. (2016). Clinical and genetic predictors and prognostic model of rapidly progressive hepatic fibrosis in chronic hepatitis C. Georgian Med News, 7–8(256–257), 37–45.
Fakhir, F. Z., Lkhider, M., Badre, W., Alaoui, R., Meurs, E. F., Pineau, P., et al. (2018). Genetic variations in toll‐like receptors 7 and 8 modulate natural hepatitis C outcomes and liver disease progression. Liver Int., 38(3), 432–442. doi: 10.1111/liv.13533
Schott, E., Witt, H., Neumann, K., Taube, S., Oh, D. Y., Schreier, E., et al. (2007). A toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol., 47(2), 203–211. doi: 10.1016/j.jhep.2007.03.021
Koval, T., Dubinskaya, G., & Sizova, L. (2017). Prognozirovanie skorosti razvitiya fibroza pecheni pri khronicheskom gepatite С u VICH-inficirovannykh pacientov [Prognosis of rapidly progressive hepatic fibrosis in HIV-infected patients with chronic hepatitis C]. Klinicheskaya infektologiya i parazitologiya, 3, 344–345. [in Russian].
Taratina, O. V., Samokhodskaia, L. M., Krasnova, T. N., & Mukhin, N. A. (2017). Prognozirovanie skorosti razvitiya fibroza pecheni u bolnyih hronicheskim gepatitom С na osnove kombinatsii geneticheskih i sredovyih faktorov [Predicting the rate of liver fibrosis in patients with chronic hepatitis C virus infection based on the combination of genetic and environmental factors]. Al'manakh klinicheskoj mediciny, 45(5), 392–407. doi: 10.18786/2072-0505-2017-45-5-392-407 [in Russian].
Schekotova, A. P., Bulatova, I. A., Schekotov, V. V., & Titov, V. N. (2016). Laboratornaya ocenka dinamiki progressirovaniya fibroza pecheni pri khronicheskom gepatite [The laboratory evaluation of dynamics of progression of liver fibrosis under chronic hepatitis]. Klinicheskaya laboratornaya diagnostika, 61(10), 686–689. doi: 10.18821/0869-2084-2016-61-10-686-689 [in Russian].
Trépo, E., Pradat, P., Potthoff, A., Momozawa, Y., Quertinmont, E., Gustot, T., et al. (2011). Impact of patatin-like phospholipase-3 (rs738409C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology, 54(1), 60–69. doi: 10.1002/hep.24350
Rüeger, S., Bochud, P. Y., Dufour, J. F., Müllhaupt, B., Semela, D., Heim, M. H., et al. (2015). Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut, 64(10), 1605–1615. doi: 10.1136/gutjnl-2014-306997
Romero-Gomez, M., Eslam, M., Ruiz, A., & Maraver, M. (2011). Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int., 31(4), 443–460. doi: 10.1111/j.1478-3231.2011.02449.x
Fontana, R. J., Litman, H. J., Dienstag, J. L., Bonkovsky, H. L, Su, G., Sterling, R. K., et al. (2012). YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int., 32(4), 665–674. doi: 10.1111/j.1478-3231.2011.02686.x
do O, N. T., Eurich, D., Schmitz, P., Schmeding, M., Heidenhain, C., Bahra, M., et al. (2012). A 7-gene signature of the recipient predicts the progression of fibrosis after liver transplantation for hepatitis C virus infection. Liver Transpl., 18(3), 298–304. doi: 10.1002/lt.22475
Sheptulina, A. F., Shirokova, Ye. N., & Ivashkin, V. T. (2015). Neinvazivnaya diagnostika fibroza pecheni: rol' syvorotochnyh markerov [Non-invasive of liver fibrosis diagnostics: the role of serum markers]. Rossijskij zhurnal gastroe'nterologii, gepatologii, koloproktologii, 2, 28–40. [in Russian].
Gudowska, M., Wojtowicz, E.,Cylwik, B., Gruszewska, E., & Chrostek, L. (2015). The distribution of liver steatosis, fibrosis, steatohepatitis and inflammation activity in alcoholics according to FibroMax Test. Adv Clin Exp Med., 24(5), 823–827. doi: 10.17219/acem/28485
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).